Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

46.2%

6 terminated/withdrawn out of 13 trials

Success Rate

45.5%

-41.0% vs industry average

Late-Stage Pipeline

15%

2 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

9(75.0%)

Phase 1

1(8.3%)

Phase 3

1(8.3%)

Phase 4

1(8.3%)

12Total

Phase 2(9)

Phase 1(1)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials

NCT00548717Phase 2Terminated

Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation

Role: collaborator

NCT00014664Phase 2Unknown

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Role: lead

NCT00279422Phase 2Terminated

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Role: collaborator

NCT00279435Phase 2Terminated

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

Role: collaborator

NCT00267306Phase 1Completed

Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis

Role: collaborator

NCT00267709Phase 2Completed

Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease

Role: collaborator

NCT00267722Phase 2Completed

Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease

Role: collaborator

NCT00502294Phase 3Withdrawn

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Role: collaborator

NCT00281294Phase 2Terminated

A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

Role: lead

NCT00109161Phase 2Completed

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Role: lead

NCT00355901Terminated

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

Role: lead

NCT00099970Phase 2Completed

Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

Role: lead

NCT00325793Phase 4Unknown

IV Double and Triple Concentrated Nicardipine for Stroke and ICH

Role: collaborator

All 13 trials loaded